Antinuclear antibodies: A marker associated with steroid dependence in patients with ulcerative colitis
暂无分享,去创建一个
J. Yamamoto-Furusho | C. Garcı́a-Martı́nez | J. Cabiedes | J. Barahona-Garrido | J. Camacho-Escobedo | H. Tocay
[1] F. Gabilondo-Navarro,et al. El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , 2010 .
[2] A. Dall'aglio,et al. Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis , 2007, Rheumatology International.
[3] J. Gisbert,et al. Papel de los marcadores biológicos en la enfermedad inflamatoria intestinal , 2007 .
[4] I. Lavi,et al. Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity , 2007, Rheumatology International.
[5] W. Sandborn,et al. Review article: biological activity markers in inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.
[6] J. Mate,et al. [Role of biological markers in inflammatory bowel disease]. , 2007, Gastroenterologia y hepatologia.
[7] L. Punzi,et al. [Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab]. , 2011, Reumatismo.
[8] D. Chang,et al. [Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis]. , 2006, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[9] A. Darzi,et al. Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease , 2006, The American Journal of Gastroenterology.
[10] J. Yamamoto-Furusho,et al. Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution. , 2006, World journal of gastroenterology.
[11] M. Majdan,et al. [Association of ulcerative colitis and lupus nephropathy--report of two cases]. , 2006, Polskie Archiwum Medycyny Wewnetrznej.
[12] F. Ajayi,et al. Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.
[13] Dhiman Basu,et al. Impact of Race and Ethnicity on Inflammatory Bowel Disease , 2005, The American Journal of Gastroenterology.
[14] A. Zinsmeister,et al. Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.
[15] C. L. Colglazier,et al. Featured CME Topic: Arthritis Laboratory Testing in the Rheumatic Diseases: A Practical Review , 2005 .
[16] M. Rizzetto,et al. The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[17] S. Endres,et al. Antinuclear Autoantibodies in Patients with Inflammatory Bowel Disease (High Prevalence in First-Degree Relatives) , 1997, Digestive Diseases and Sciences.
[18] E. Veys,et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. , 2003, Arthritis and rheumatism.
[19] G. Porro,et al. Inflammatory bowel disease: new insights into pathogenesis and treatment , 2002, Journal of internal medicine.
[20] A. Zinsmeister,et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.
[21] J. Mccrea,et al. A case of Sjögren's syndrome, sarcoidosis, previous ulcerative colitis and gastric autoantibodies , 1996, The British journal of dermatology.
[22] E. Soppi,et al. Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. , 1995, Journal of clinical pathology.
[23] J. Priddle,et al. Serum and tissue autoantibodies to colonic epithelium in ulcerative colitis. , 1991, Gut.
[24] S. Procaccia,et al. Detection of rheumatoid factors of different isotypes and of circulating immune complexes in patients with inflammatory bowel disease. , 1990, Bollettino dell'Istituto sieroterapico milanese.
[25] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.
[26] E. Schrumpf,et al. An autoantibody profile in primary sclerosing cholangitis. , 1987, Journal of hepatology.
[27] F. Bianchi,et al. Antibodies to the cytoskeleton components and other autoantibodies in inflammatory bowel disease. , 1985, Digestion.